Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6 months of therapy in cats using different IV infusion durations

Molecular Genetics and Metabolism

Volumn 117, Issue 2, 2016, Pages 157-163

  Ruane, Therese ^a   Haskins, Mark ^a   Cheng, Alphonsus ^d   Wang, Ping ^a   Aguirre, Gustavo ^b   Knox, Van W ^c   Qi, Yulan ^d   Tompkins, Troy ^d   O'Neill, Charles A ^d  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BioMarin Pharmaceutical Inc ^*  (United States)

^d BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Enzyme replacement therapy; Galsulfase; Infusion duration; Maroteaux Lamy syndrome; Mucopolysaccharidosis VI; Recombinant human N acetylgalactosamine 4 sulfatase

Indexed keywords

BETA GLUCURONIDASE; GALSULFASE; GLYCOSAMINOGLYCAN; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOCHEMICAL ANALYSIS; CAT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ENZYME ACTIVITY; FEMALE; MALE; MAROTEAUX LAMY SYNDROME; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; SKELETON MALFORMATION; TREATMENT OUTCOME; URINARY EXCRETION; ANIMAL; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; ENZYME REPLACEMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOPOLYSACCHARIDOSIS VI; PRECLINICAL STUDY; TISSUE DISTRIBUTION; URINE;

ANIMALS; CATS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 84957846917     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2015.10.006     Document Type: Article

References (27)

1. Valayannopoulos V., Nicely H., Harmatz P., Turbeville S. Mucopolysaccharidosis VI. Orphanet J. Rare Dis. 2010, 5:5.
2. Naglazyme® (galsulfase) solution for intravenous infusion only, [prescribing information 2005, BioMarin Pharmaceutical Inc., Novato, CA.
3. Crawley A.C., Brooks D.A., Muller V.J., Petersen B.A., Isaac E.L., Bielicki J., King B.M., Boulter C.D., Moore A.J., Fazzalari N.L., Anson D.S., Byers S., Hopwood J.J. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest. 1996, 97:1864-1873.
4. Harmatz P., Kramer W.G., Hopwood J.J., Simon J., Butensky E., Swiedler S.J., Mucopolysaccharidosis VI study group Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr. Suppl. 2005, 94:61-68.
5. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., Yu Z.F., Swiedler S.J., Hopwood J.J., MPS VI study group Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005, 115:e681-e689.
6. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
7. Harmatz P.R., Garcia P., Guffon N., Randolph L.M., Shediac R., Braunlin E., Lachman R.S., Decker C. Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. J. Inherit. Metab. Dis. 2014, 37:277-287.
8. Kim K.H., Decker C., Burton B.K. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). Pediatrics 2008, 121:e714-e717.
9. Bagewadi S., Roberts J., Mercer J., Jones S., Stephenson J., Wraith J.E. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J. Inherit. Metab. Dis. 2008, 31:733-737.
10. Haskins M.E., Aguirre G.D., Jezyk P.F., Patterson D.F. The pathology of the feline model of mucopolysaccharidosis VI. Am. J. Pathol. 1980, 101:657-674.
11. Sleeper M.M., Kusiak C.M., Shofer F.S., O'Donnell P., Bryan C., Ponder K.P., Haskins M.E. Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI. J. Inherit. Metab. Dis. 2008, 31:424-431.
12. Byers S., Nuttall J.D., Crawley A.C., Hopwood J.J., Smith K., Fazzalari N.L. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 1997, 21:425-431.
13. Auclair D., Hein L.K., Hopwood J.J., Byers S. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval. Pediatr. Res. 2006, 59:538-543.
14. Auclair D., Hopwood J.J., Lemontt J.F., Chen L., Byers S. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI. Mol. Genet. Metab. 2007, 91:352-361.
15. Auclair D., Finnie J., Walkley S.U., White J., Nielsen T., Fuller M., Cheng A., O'Neill C.A., Hopwood J.J. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr. Res. 2012, 71:39-45.
16. Lachman R., Martin K.W., Castro S., Basto M.A., Adams A., Teles E.L. Radiologic and neuroradiologic findings in the mucopolysaccharidoses. J. Pediatr. Rehabil. Med. 2010, 3:109-118.
17. Auclair D., Finnie J., White J., Nielsen T., Fuller M., Kakkis E., Cheng A., O'Neill C.A., Hopwood J.J. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol. Genet. Metab. 2010, 99:132-141.
18. Chang P.L., Rosa N.E., Davidson R.G. Differential assay of arylsulfatase A and B activities: a sensitive method for cultured human cells. Anal. Biochem. 1981, 117:382-389.
19. Fyfe J.C., Kurzhals R.L., Lassaline M.E., Henthorn P.S., Alur P.R., Wang P., Wolfe J.H., Giger U., Haskins M.E., Patterson D.F., Sun H., Jain S., Yuhki N. Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. Genomics 1999, 58:121-128.
20. Taylor E.H. Clinical Chemistry 1989, John Wiley and Sons, New York.
21. Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalás O., Pinto L.L., Azevedo A.C., Acosta A., Bonfim C., Lourenço C.M., Kim C.A., Horovitz D., Bonfim D., Norato D., Marinho D., Palhares D., Santos E.S., Ribeiro E., Valadares E., Guarany F., de Lucca G.R., Pimentel H., de Souza I.N., Correa J., Fraga J.C., Goes J.E., Cabral J.M., Simionato J., Llerena J., Jardim L., Giuliani L., da Silva L.C., Santos M.L., Moreira M.A., Kerstenetzky M., Ribeiro M., Ruas N., Barrios P., Aranda P., Honjo R., Boy R., Costa R., Souza C., Alcantara F.F., Avilla S.G., Fagondes S., M.AM Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet. Mol. Biol. 2010, 33:589-604.
22. Giugliani R., Harmatz P., Wraith J.E. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007, 120:405-418.
23. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., Kania S., Bedolla C., Chien S.L., Shull R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 1996, 58:156-167.
24. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
25. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J. Pediatr. 2004, 44:581-588.
26. Crawley A., Ramsay S.L., Byers S., Hopwood J., Meikle P.J. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry. Pediatr. Res. 2004, 55:585-591.
27. Byers S., Crawley A.C., Brumfield L.K., Nuttall J.D., Hopwood J.J. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr. Res. 2000, 47:743-749.